U2AF1 and cancer: For example, in MDS, MPN, MDS/MPN, and secondary AML (sAML), U2AF1 (U2AF35) mutations, which are observed in 1–10% of de novo AML, have been found associated with abnormal splicing of genes involved in cell cycle progression and RNA processing that are somatically mutated or deleted in various cancers [13].